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Background: Maternal use of corticosteroids during early pregnancy has been
inconsistently associated with orofacial clefts in the offspring. A previous
report from the National Birth Defect Prevention Study (NBDPS), using data
from 1997 to 2002, found an association with cleft lip and palate (odds ratio,
1.7; 95% confidence interval [CI], 1.1–2.6), but not cleft palate only (odds
ratio, 0.5, 95%CI, 0.2–1.3). From 2003 to 2009, the study population more
than doubled in size, and our objective was to assess this association in the
more recent data. Methods: The NBDPS is an ongoing multi-state population-
based case-control study of birth defects, with ascertainment of cases and
controls born since 1997. We assessed the association of corticosteroids and
orofacial clefts using data from 2372 cleft cases and 5922 controls born from
2003 to 2009. Maternal corticosteroid exposure was based on telephone
interviews. Results: The overall association of corticosteroids and cleft lip and
palate in the new data was 1.0 (95% CI, 0.7–1.4). There was little evidence
of associations between specific corticosteroid components or timing and
clefts. Conclusion: In contrast to the 1997 to 2002 data from the NBDPS, the
2003 to 2009 data show no association between maternal corticosteroid use
and cleft lip and palate in the offspring.
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Introduction
Orofacial clefts are one of the most common birth defects
in humans, with a world birth prevalence of 1.7 per 1000
live births (Mossey et al., 2009). Orofacial clefts occur
when the fusion of the lip and/or palate, which takes
place during the first-trimester of pregnancy, is disrupted
(Dixon et al., 2011). Corticosteroids are well-established as
an experimental teratogen in animal models, causing cleft
palate in mice (Fraser and Fainstat, 1951; Walker and
Fraser, 1957). Several epidemiological studies have
reported an association between corticosteroid use in
early pregnancy in humans and delivering an infant with
an orofacial cleft (Czeizel and Rockenbauer, 1997;
Rodrıguez-Pinilla and Luisa Martınez-Frıas, 1998; Carmi-
chael and Shaw, 1999; Edwards et al., 2003; Pradat et al.,
2003; Carmichael et al., 2007), although others have not
(Kallen et al., 1999; K€allen, 2003; Hviid and Mlgaard-
Nielsen, 2011).
The anti-inflammatory and immune modulating func-
tions of corticosteroids are effective in the treatment of
conditions such as asthma, allergic reactions, eczema, pso-
riasis, rheumatoid arthritis, and inflammatory bowel dis-
ease. These conditions are common and often affect
women of reproductive age; however, the safety of cortico-
steroid medication during pregnancy is uncertain.
We previously reported that maternal corticosteroid use
was associated with increased risk of cleft lip with or with-
out palate (CLP) (odds ratio [OR], 1.7; 95% confidence inter-
val [CI], 1.1–2.6) but not cleft palate only (CPO) (OR, 0.5;
95%CI, 0.2–1.3), using data from the National Birth Defects
Prevention Study (NBDPS) investigating deliveries from
October 1997 through December 2002, including mothers of
1141 infants with CLP, 628 infants with CPO and 4143 con-
trols (Carmichael et al., 2007). Since then, the study popula-
tion has more than doubled in size, allowing the largest
study of corticosteroids and clefts to date. Given continued
uncertainty about the association between orofacial clefts
and corticosteroid medications and the tentative findings
from our earlier analyses, our objective here was to assess
the association using larger and more recent NBDPS data.
Materials and Methods
We used data from the NBDPS, a population-based, multi-
center case–control study of birth defects. Information on
deliveries taking place from October 1997 through Decem-
ber 2009 was collected from the 10 NBDPS study centers
(Arkansas, California, Georgia, Iowa, Massachusetts, New
Jersey, New York, North Carolina, Texas, and Utah),
although not all study sites contributed for all the study
years. The study was approved by institutional review
boards of the participating centers and the Centers for
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Disease Control and Prevention. More details on study
methods and its surveillance systems can be found else-
where (Yoon et al., 2001; Rasmussen et al., 2003).
Infants or fetuses with CLP or CPO were considered
cases and analyzed separately. Case status was ascertained
either through clinical or surgical records or autopsy
reports. Medical records for all cases were assessed by a
clinical geneticist who ensured that they fulfilled the eligi-
bility criteria. Cases were ineligible if their clefts were
believed to result from another defect (e.g., holoprosence-
phaly) or had a recognized or strongly suspected single-
gene disorder or chromosomal abnormality. Cases were
considered isolated if there were no accompanying major
unrelated birth defects or as nonisolated if more than one
additional major unrelated defect was present. Controls
(live born infants, without birth defects) were randomly
selected from hospital birth records or birth certificates at
each study center.
Mothers were interviewed 6 weeks to 24 months after
estimated date of delivery, using computer-assisted telephone
interviews in English or Spanish; median time between esti-
mated date of delivery and interview was 9.0 months for
case mothers (interquartile range 8.0 months) and 8.0
months for controls (interquartile range 7.0 months). Overall
participation from 1997 to 2009 was 72% for eligible moth-
ers of infants with clefts and 65% for control mothers (par-
ticipation in the two time periods declined from 76% to 67%
for eligible mothers of infants with clefts and 68% to 61%
for control mothers, with an overall decline from 70% to
63%).
In the questionnaires the mothers were asked whether
they had specific medical conditions before or during preg-
nancy and then what medications they used to treat them.
Mothers were also asked to list any other medication they
had used that was not captured in response to the specific
questions; indication was not reported for responses to this
question. Mothers were asked for duration and frequency
of use for each medication used from 12 weeks before con-
ception to delivery. Medications were coded according to
the Slone Epidemiology Center Drug Dictionary. We focused
on periconceptional corticosteroid use by any administra-
tion route and component (systemic, nasal/inhaled and
topical), defined as use that occurred between 4 weeks
before through 12 weeks after conception.
We investigated the association between any cortico-
steroid use during the periconceptional period compared
with no use. We also explored whether there was an asso-
ciation with specific timing of exposure, mode of adminis-
tration, or corticosteroid component. Logistic regression
models in SAS software were used to estimate ORs and
their corresponding 95% CIs. ORs were only calculated if
there were two or more exposed cases and two or more
exposed controls. We also examined associations after
adjustment for several covariates (maternal race-ethnicity,
education, intake of folic acid-containing supplements,
smoking, and study center) and after exclusion of noniso-
lated cases. We present results for deliveries from January
2003 through December 2009, and for pooled data for
deliveries from October 1997 through December 2009.
Results
From 2003 to 2009, the NBDPS enrolled mothers of 1577
children with CLP, 795 children with CPO, and 5922 control
children. Demographic characteristics are outlined in Table 1.
A total of 89% of the CLP cases (n5 1402) and 79% of CPO
cases (n5 631) were isolated. Any use of corticosteroids
four weeks prior through 12 weeks after conception was
reported by mothers of 35 (2.3%) infants with CLP (OR, 1.0;
95% CI, 0.7–1.4) and mothers of 13 (1.7%) infants with CPO
(OR, 0.7; 95% CI, 0.4–1.2), and by mothers of 137 (2.4%)
control infants (Table 2). There was no association by route
of administration (systemic, nasal/inhaled, topical or other
use) or specific components of corticosteroids (Prednisone,
TABLE 1. Characteristics of mothers of 1577 infants with cleft lip with or with-
out cleft palate (CLP), 795 infants with cleft palate only (CPO), and 5922 non-
malformed control infants
Percent (n)a
Variable CLP CPO Controls
Race/ethnicity
Non-Hispanic white 59 (925) 59 (470) 56 (3330)
Non-Hispanic black 6 (92) 8 (62) 10 (618)
Hispanic 27 (426) 23 (182) 25 (1457)
Other 8 (133) 10 (81) 9 (507)
Unknown <1 (1) 0 <1 (10)
Education
<High school graduation 20 (316) 17 (134) 17 (997)
High school graduation 27 (421) 26 (206) 23 (1347)
1–3 years of college 25 (391) 28 (223) 26 (1529)
41 years college 27 (418) 27 (213) 31 (1860)
Unknown 2 (31) 2 (19) 3 (189)
Smoking
Any 22 (343) 21 (168) 17 (1008)
None 76 (1204) 77 (610) 80 (4744)
Unknown 2 (30) 2 (17) 3 (170)
Intake of folic acid-containing supplementsb
Any 84 (1326) 84 (668) 85 (5046)
None 14 (222) 13 (105) 12 (726)
Unknown 2 (29) 3(22) 3 (150)
NBDPS deliveries 2003–2009.
aPercentages may not add to 100% because of rounding.
bDuring the month before and first 3 months of pregnancy.
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TABLE 2. Association of Risk of Cleft Lip and Palate (CLP) and Cleft Palate Only (CPO) among Offspring Born to Women Who Used Maternal Corticosteroid Medi-
cations from 4 Weeks before through 12 Weeks after Conception, by Route of Administration and Component Corticosteroid.
Route of administration
and component
N Odds Ratio (95% CI)a N Odds Ratio (95% CI)a N Odds rratio (95% CI)a
1997–2002 1997–2002 2003-09 2003-09 1997–2009 1997–2009
Any use
CLP 33 1.7 (1.1, 2.6) 35 1.0 (0.7, 1.4) 69 1.2 (0.9, 1.6)
CPO 6 0.5 (0.2-1.3) 13 0.7 (0.4, 1.2) 19 0.6 (0.4, 1.0)
Controls 72 137 214
Any systemic use
CLP 9 2.1 (0.9, 4.7) 9 1.3 (0.6, 2.8) 18 1.6 (0.9, 2.8)
CPO 2 0.8 (0.2–3.6) 3 0.9 (0.3, 2.8) 5 0.8 (0.3, 2.1)
Controls 16 26 42
Prednisone
CLP 8 2.7 (1.1, 6.7) 6 1.4 (0.6, 3.6) 14 1.9 (1.0, 3.7)
CPO 2 1.2 (0.3–5.4) 1 – 3 0.8 (0.2, 2.6)
Controls 11 16 27
Any nasal spray/inhaled use
CLP 19 1.5 (0.9, 2.5) 26 1.0 (0.7, 1.6) 46 1.2 (0.8, 1.6)
CPO 5 0.7 (0.3, 1.8) 11 0.8 (0.5, 1.6) 16 0.8 (0.5, 1.3)
Controls 47 96 148
Beclomethasone
CLP 5 1.7 (0.6, 4.8) 0 – 5 1.7 (0.6, 4.8)
CPO 2 1.2 (0.3, 5.4) 0 – 2 1.3 (0.3, 5.7)
Controls 11 0 11
Budesonide
CLP 3 2.8 (0.6, 12.3) 1 – 4 0.7 (0.3, 2.2)
CPO 2 3.3 (0.6, 17.9) 1 – 3 1.0 (0.3, 3.5)
Controls 4 16 20
Fluticasone
CLP 8 1.3 (0.6, 2.9) 18 1.0 (0.6, 1.6) 26 1.0 (0.7, 1.6)
CPO 0 – 7 0.7 (0.3, 1.6) 7 0.5 (0.2, 1.1)
Controls 23 70 93
Triamcinolone
CLP 5 2.0 (0.7, 6.1) 2 1.9 (0.3, 10.3) 7 2.0 (0.8, 5.0)
CPO 1 – 0 – 1 –
Controls 9 4 13
Any topical use
CLP 2 0.9 (0.2, 4.3) 1 – 3 0.5 (0.2, 1.7)
CPO 0 – 0 – 0 –
Controls 8 14 22
Other use
CLP 4 2.9 (0.8, 11.0) 0 – 4 2.5 (0.7, 8.8)
CPO 0 – 0 – 0 –
Controls 5 1 6
NBDPS deliveries 2003 to 2009*.
aReference groups for the comparisons for the two time intervals included: 2003-09: 1542 CLP cases, 782 CPO cases, and 5785 controls with
no exposure from 4 weeks before through 12 weeks after conception; 1997–2009: 2662 CLP cases, 1410 CP cases, and 9849 controls with
no exposure from 4 weeks before through 12 weeks after conception. Odds ratios were estimated only if there were at least two exposed cases
and two exposed controls.
Beclomethasone, Budesonide, Fluticasone, Triamcinolone).
Furthermore, we did not find associations at more specific
time windows of exposure (Table 3).
By combining the earlier data with more recent data,
the total cohort included mothers of 2731 infants with
CLP, 1429 infants with CPO, and 10063 controls, delivered
from October 1997 through December 2009. Mothers of
69 (2.6%) infants with CLP (OR 1.2 95% CI, 0.9–1.6), 19
(1.3%) infants with CPO (OR 0.6, 95% CI, 0.4–1.0) and
214 (2.1%) controls reported using any corticosteroids
from 4 weeks before 12 weeks after gestation (Table 2).
We did not find an association by route of administration
or component of corticosteroid in the combined data, with
the possible exception of prednisone (OR, 1.9; 95% CI,
1.0–3.7) (Table 2). Results by time window of exposure
were inconsistent (Table 3). For CLP, odds ratios ranged
from 2.8 (95% CI, 1.3–5.9) for exposures only during
week 1 to 4 and 5 to 8 after conception to 0.5 (95% CI,
0.1–1.6) for exposures during weeks 9 to 12.
For analyses of any corticosteroid use we adjusted for
maternal race-ethnicity (Non-Hispanic white, Non-Hispanic
black, Hispanic, Other, and unknown), education (<High
school graduation, High school graduation, 1–3 years of col-
lege, 4years of college and unknown), intake of folic acid
(any, none, and unknown), smoking (any [active], none,
unknown), and study center (Arkansas, California, Georgia,
Iowa, Massachusetts, New Jersey, New York, North Carolina,
Texas, and Utah), and we excluded nonisolated cases in the
pooled data. We conducted additional analyses restricting to
states that participated in the study for the whole time
period (Arkansas, California, Georgia, Iowa, Massachusetts,
New York, and Texas). These modifications did not appreci-
ably change our estimates. Length of time to interview was
slightly shorter for mothers reporting corticosteroid use.
This was true for both cases (mean time 9.2 months for
mothers reporting corticosteroid use and 10.5 for no use)
and controls (mean time 8.2 months for mothers reporting
corticosteroid use and 9.1 for no use).
The main results from the two time periods (1997–
2002 vs. 2003–2009) are illustrated in Figure 1.
Discussion
Recent data from the NBDPS provided no support for an
association between maternal corticosteroid use during early
pregnancy and delivering an infant with an orofacial cleft.
This is in contrast to results from the first 6 years of the
NBDPS, for which there was an association with CLP but not
CPO (Carmichael et al., 2007). The component of corticoste-
roid most strongly associated with delivering an infant with
CLP in the data from 1997 to 2002 was systemic prednisone;
OR 2.7 (95% CI 1.1–6.7). This association was much weaker
in the data from 2003 to 2009; OR 1.4 (95% CI 0.6–3.6).
When comparing corticosteroid use between the
early and more recent data (1997–2002 vs. 2003–2009)
there was increased use among controls (1.7–2.4%) and
CPO cases (1.0–1.7%), however, there was a decrease
among CLP cases (2.9 to 2.3%). This resulted in weaker
associations with CLP in the more recent data. We are
not aware of any significant changes in the study proto-
col, case ascertainment, or recruitment of cases or con-
trols that could explain these differences. Given the
small numbers, it is not possible to determine whether
the frequency of reported use represents a trend or lies
within the range of normal variation. We therefore sug-
gest that our best estimates of the association of corti-
costeroids and orofacial clefts in the NBDPS data are
those derived from the pooled data. Participation rates
declined over the two time periods, from 70% to 63%
overall. While this decline is substantial, participation is
still in a range usually regarded as acceptable for obser-
vational studies.
The strongest association by component observed in
the pooled data was for CLP and prednisone (OR, 1.9;
95% CI, 1.0–3.7). The number of control mothers report-
ing use of prednisone was stable at 0.3% during both time
periods (1997–2002 and 2003–2009), while the propor-
tion of case mothers (CLP) reporting prednisone went
down from 0.7% to 0.4%. Given the substantial difference
between the association in the earlier and later data (ORs
of 2.7 vs. 1.4), and its marginal statistical significance, we
recommend interpreting this result with caution. This also
applies to associations between corticosteroid exposures
by specific time period, because they were so variable. The
strongest finding was for exposures during week 1 to 4
and 5 to 8 after conception (OR, 2.8; 95% CI, 1.3, 5.9, for
the pooled data). The OR in the early data was 7.3 (95%
CI, 1.8–29.4) and in the later data 1.9 (95% CI, 0.7–5.0).
Although we recommend interpreting these results with
caution, an association by timing of exposure cannot be
dismissed completely. For comparison, a large US study
reported that 0.8% of women received first trimester pre-
scriptions for systemic corticosteroids (Andrade et al.,
2004), with actual medication use probably less than
100% (Olesen et al., 2001). Furthermore, the prevalence is
similar to what has been found in the National Health and
Nutrition Examination Study (NHANES) during the years
1999 to 2008, where 0.5% of women aged 20 to 29 years
and 0.6% of women aged 30 to 39 years reported use of
oral corticosteroids (Overman et al., 2013). The NHANES
data also indicate a trend toward lower prevalence of oral
corticosteroid use from 1999 to 2008.
The earliest report of corticosteroids causing clefts was
a study in mice (Fraser and Fainstat, 1951). Since then,
studies have shown that corticosteroids are involved in
cellular processes that lead to fusion of the palatal shelves,
which can be disrupted by altering physiological cortico-
steroid levels (Pratt and Salomon, 1980; Piddington et al.,
1983; Ziejewski et al., 2012). Studies have shown that ter-
atogenicity can vary across species (Nau, 1986). Such
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TABLE 3. Association of Risk of Cleft Lip and Palate (CLP) among Offspring Born to Women Who Used Corticosteroids, by Timing of Exposure
Exposure time period
N Odds ratio (95% CI)a N Odds ratio (95% CI)a N Odds ratio (95% CI)a
1997–2002 1997–2002 2003-09 2003-09 1997–2009 1997–2009
Any exposure from 4 weeks before
conception through 12 weeks
after conception
CLP 33 1.7 (1.1, 2.6) 35 1.0 (0.7, 1.4) 69 1.2 (0.9, 1.6)
Controls 72 137 214
Exposed only during 4 weeks
before conception
CLP 5 2.3 (0.8, 7.0) 4 2.5 (0.7, 8.9) 9 2.4 (1.0, 5.5)
Controls 8 6 14
Pregnancy exposure only
during weeks 1–4 after
conception
CLP 3 1.4 (0.4, 5.2) 1 – 5 0.7 (0.3, 1.9)
Controls 8 17 26
Pregnancy exposure only
during weeks 5–8 after
conception
CLP 1 – 0 – 1 –




CLP 2 0.7 (0.1, 3.0) 1 – 3 0.5 (0.1, 1.6)
Controls 11 11 23
Pregnancy exposure
during weeks 1–4 and
5–8 after conception
CLP 6 7.3 (1.8, 29.4) 6 1.9 (0.7, 5.0) 12 2.8 (1.3, 5.9)
Controls 3 12 16
Pregnancy exposure
during weeks 5–8 and
9–12 after conception
CLP 1 – 3 2.3 (0.5, 9.5) 4 2.1 (0.6, 7.2)
Controls 2 5 7
Pregnancy exposure
during weeks 1–4, 5–8, and
9–12 after conception
CLP 15 1.4 (0.8, 2.6) 20 0.9 (0.6, 1.5) 35 1.1 (0.7, 1.6)
Controls 39 80 121
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studies have involved systemic corticosteroids, at doses
that are 15 to 150 times human doses; thus, their compa-
rability to the human condition is uncertain.
Previous epidemiological studies on corticosteroid use
during early pregnancy and the risk of delivering an infant
with an orofacial cleft are outlined in Table 4. Systemic
corticosteroid use in early pregnancy has been associated
with delivering an infant with CLP in some previous epide-
miological studies in humans (Czeizel and Rockenbauer,
1997; Rodrıguez-Pinilla and Luisa Martınez-Frıas, 1998;
Carmichael and Shaw, 1999; Pradat et al., 2003; Carmi-
chael et al., 2007), one of which also reported an associa-
tion with CPO (Carmichael and Shaw, 1999). Studies from
Denmark, Norway, Sweden have found no association with
systemic use in early pregnancy and orofacial clefts in the
offspring, and a weak association with dermatological cor-
ticosteroids (K€allen, 2003; Hviid and Mlgaard-Nielsen,
2011; Skuladottir et al., 2013). However, a recent
population-based cohort study from the UK did not find
an association between dermatological corticosteroids and
clefts (Chi et al., 2013). In sum, the current literature is
inconsistent regarding the association of first-trimester
corticosteroid use and orofacial clefts in humans. The pre-
vious studies are limited by sample size, with number of
cases (CLP and CPO combined) ranging from 8 to 1232.
The NBDPS included 4072 pregnancies resulting in
either CLP or CPO, with 23 (0.6%) mothers reporting sys-
temic corticosteroid use, making it the largest study
exploring this potential association to date. Other
strengths include the population-based design and the
detailed assessment on corticosteroid mode, specific com-
ponent used and the detailed time windows of exposure.
We lacked information on dose and indication, which were
limitations. Other potential limitations include recall bias
(mean time to interview was slightly shorter for the moth-
ers who reported corticosteroid use than the mothers who
did not report use) and selection bias (participation was
72% for case mothers and 65% for control mothers). In
the NBDPS questionnaire, there is no specific question for
dermatological disease or treatment, and dermatological
TABLE 3. Continued
Exposure time period
N Odds ratio (95% CI)a N Odds ratio (95% CI)a N Odds ratio (95% CI)a
1997–2002 1997–2002 2003-09 2003-09 1997–2009 1997–2009
Any exposure during weeks
1–4 or 5–8 after
conception
CLP 26 1.8 (1.1, 2.9) 30 0.9 (0.6, 1.6) 57 1.2 (0.9, 1.6)
Controls 53 120 177
NBDPS Deliveries 2003–2009.
aReference groups for the comparisons for the two time intervals included: 2003-09: 1542 CLP cases, 782 CPO cases, and 5785 controls with
no exposure from 4 weeks before through 12 weeks after conception; 1997–2009: 2662 CLP cases, 1410 CP cases, and 9849 controls with
no exposure from 4 weeks before through 12 weeks after conception. Odds ratios were estimated only if there were at least two exposed cases
and two exposed controls.
FIGURE 1. Association of risk of
cleft lip and palate (CLP) among
offspring born to women who used
maternal corticosteroid medications
from 4 weeks before through 12
weeks after conception, comparing
NBDPS deliveries 1997 to 2002
versus 2003 to 2009. Results are
presented in a logarithmic scale.
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TABLE 4. Summary of Previous Epidemiological Studies on Corticosteroid Use during Pregnancy and Risk of Orofacial Clefts
Country/study design/ Relative risk estimates (95% CI)
Study (year) exposure assessment Mode All CLP CP




Hviid & Molgaard- Denmark/ Any 1.1 (0.8, 1.4) 1.2 (0.8, 1.8)
Nielsen (2013) Population-based Inhaled 0.8 (0.3, 1.7) 0.9 (0.3, 2.9)
Birth Cohort/ Nasal 0.5 (0.2, 1.2) 1.1 (0.4, 2.6)
Prescription Dermatologic 1.5 (1.0, 2.1) 1.5 (0.9, 2.5)
Drug Registry Other topical 1.0 (0.6, 1.8) 1.0 (0.4, 2.3)
Carmichael et al USA/ Any 1.7 (1.1, 2.6) 0.5 (0.2, 1.3)
(2007) Population-based Systemic 2.1 (0.9, 4.7) 0.8 (0.2, 3.6)
Case-control/ Nasal 1.5 (0.9, 2.5) 0.7 (0.1, 1.8)
Questionnaire Topical 0.9 (0.2, 4.3) 0
Kallen et al (2003) Sweden/ Any 1.4 (1.0, 2.0) 1.1 (0.6, 1.9) 1.8 (0.9, 3.2)
Population-based Systemic 1.9 (0.8, 4.0)
Birth Cohort/ Inhaled 1.2 (0.7, 1.9)
Medical Nasal drops 1.4 (0.6, 2.9)
Birth registry Topical 2.0 (0.6, 5.2)
Edwards et al (2003) Australian/
Hospital-based
Case-control/
Topical 13.2 (1.7, 586) 11.7 (1.4, 537) 12.0 (1.1, 600)
Questionnaire
Pradat et al (2003) Multi National/ Intestinal 0.6 (0.1, 2.9) 0 3.0 (0.7, 13)
9 Birth Dermatologic 0.5 (0.2, 1.6) 0.7 (0.2, 2.4) 0
Defect Registries Systemic 1.3 (0.9, 2.0) 1.8 (1.0, 3.1) 0.3 (0.0, 1.5)
Case-control Systemic combined 2.1 (1.0, 4.3) 2.6 (1.2, 5.7) 1.2 (0.3, 4.9)
Inhaled 0.6 (0.2, 1.7) 0.7 (0.2, 2.2) 0.6 (0.1, 5.1)










Spain/ Hospital-based Systemic 5.2 (1.5, 17.1) 8.9 (2.0, 38)
Case-control
Czeizel et al (1997) Hungary/ Oral 1.27 (0.8, 2.0)
Population-based Topical 2.21 (1.1, 4.4)
Case-control/
Questionnaire
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medication is consequently underreported and estimates
are therefore inaccurate. Under-reported use of other
types of corticosteroids is also possible but difficult to
determine.
Conclusion
Maternal use of corticosteroids is not associated with
delivering an infant with an orofacial cleft in the NBDPS.
This analysis is consistent with recent results from large
population-based studies (K€allen, 2003; Hviid and
Mlgaard-Nielsen, 2011; Skuladottir et al., 2013). These
data help to inform the clinical risk-benefit decision for
use of corticosteroids during the first trimester of
pregnancy.
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